在乳腺癌中通过碳水化合物结合的PROTACs来促进GLUTs的向BRD4降解
Yunyun Gao1, Dan Ni1, Yueying Li1
1Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Journal of medicinal chemistry
|August 15, 2025
概括
这项研究引入了碳水化合物结合型蛋白解酶向化马体 (PROTACs),用于向癌症治疗. 新型化合物NG-2有效降解GLUTs过度表达细胞中的癌症蛋白质,显示毒性降低并抑制瘤生长.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 化向化体 (PROTACs) 通过降解细胞内蛋白质,为癌症提供了一种新的治疗策略.
- 由于非特异性目标蛋白质降解,PROTACs的临床转化受到组织外毒性的阻碍.
- 有针对性的输送策略对于提高PROTAC的疗效和尽量减少副作用至关重要.
研究的目的:
- 开发一种使用碳水化合物结合的瘤选择性PROTAC输送策略.
- 研究新型碳水化合物-PROTAC结合物的针对癌细胞向蛋白质降解的疗效.
- 评估化合物的体内治疗潜力和安全性.
主要方法:
- 设计和合成两个系列的碳水化合物和基和额外终端图案 (BET) PROTAC (ARV-771) 结合物.
- 评估癌细胞中的BRD4降解,评估度和时间依赖性.
- 在体外和体内研究证实GLUTs依赖性,蛋白酶依赖性,瘤选择性和治疗疗效.
主要成果:
- 合成的碳水化合物-PROTAC合物有效地以剂量和时间依赖的方式降解BRD4.
- 化合物NG-2表现出最高的降解效率,并证明在过度表达GLUT的癌细胞中具有选择性向和降解.
- 在体内,NG-2显著抑制了瘤生长,没有观察到显著的毒性.
结论:
- 碳水化合物结合为实现PROTACs瘤选择性输送提供了一个可行的策略.
- NG-2 是一个有前途的向癌症治疗剂,具有最小的组织外向降解.
- 这种方法有可能开发出更安全,更有效的基于PROTAC的癌症疗法.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Enzyme-linked Receptors
80.0K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
80.0K


